Professor Jun Zhou from Shanghai GoBroad Cancer Hospital and China Pharmaceutical University discusses the pivotal findings of the CheckMate 649 study. This landmark trial has redefined the first-line treatment for advanced gastric cancer, showcasing the power of immunotherapy combined with chemotherapy.
With groundbreaking results, including a median overall survival of 15.5 months for select patients, this study highlights the importance of dynamic trial designs, innovative biomarkers, and patient-specific strategies. Watch now to learn how these findings are shaping the future of cancer treatment.
